SYN - SYN STOCK NEWS

Synthetic Biologics, Inc. (NYSE American: SYN) announced that VCN Biosciences' VCN-01 received Orphan Drug Designation for retinoblastoma from the FDA. This designation offers benefits such as potential market exclusivity for seven years and tax credits for clinical trials. The announcement comes after Synthetic Biologics entered a definitive agreement to acquire VCN, which is developing therapies aimed at enhancing tumor cell death and immune cell infiltration. The acquisition is expected to close in Q1 2022, pending governmental approvals.

Synthetic Biologics, Inc. (NYSE American: SYN) announces its participation in the virtual B. Riley Securities Oncology Conference on January 27-28, 2022. CEO Steven Shallcross and other key management will present on January 28 at 2:30 PM ET. The presentation will be accessible live and a replay will be available on the company's website post-event. Synthetic Biologics focuses on developing therapeutics for unmet medical needs and recently agreed to acquire VCN Biosciences, which specializes in oncolytic adenoviruses aimed at treating tumors. More details can be found on their website.

Synthetic Biologics (NYSE American: SYN) announced a definitive agreement to acquire VCN Biosciences for $4.7 million in cash, plus assumption of $2.4 million in liabilities. VCN will also receive 19.99% of Synthetic's total shares outstanding. The acquisition includes potential milestone payments totaling $70.3 million. VCN’s technology focuses on overcoming challenges in oncolytic virus therapies, offering systemic delivery for treating aggressive cancers, notably pancreatic cancer. The transaction is expected to close in Q1 2022, pending regulatory approvals.

Synthetic Biologics (NYSE American: SYN) provided a clinical update and Q3 2021 financial results on November 3, 2021. The company initiated a Phase 1 clinical study of SYN-020 and continues its Phase 1b/2a trial of SYN-004 in hematopoietic cell transplant patients. As of September 30, 2021, cash reserves stood at approximately $72.1 million. R&D expenses surged by 116% to $2.0 million, while general and administrative expenses increased by 9% to $1.3 million. The net loss for Q3 2021 was $3.3 million, with an EPS loss of $0.02, reflecting ongoing investments in key clinical trials.

Synthetic Biologics, Inc. (NYSE American: SYN) announced plans to release its operational highlights and financial results for Q3 2021 on November 3, 2021, at 4:30 p.m. ET. The conference call will provide insights into the company’s performance in developing microbiome-based therapeutics aimed at gastrointestinal diseases. Key candidates include SYN-004, designed to mitigate harmful effects of IV beta-lactam antibiotics, and SYN-020, an oral enzyme formulation targeting GI and systemic conditions. Dial-in details for the call have been provided for interested participants.

Synthetic Biologics, Inc. (NYSE American: SYN) has announced the commencement of enrollment and dosing for its Phase 1, placebo-controlled clinical study of SYN-020, an intestinal alkaline phosphatase (IAP). This study aims to evaluate SYN-020's safety and tolerability in 32 healthy adult volunteers across four cohorts. With SYN-020 targeting gastrointestinal diseases, including celiac disease and non-alcoholic fatty liver disease, the company is positioned to address a significant unmet market need, projecting 4.3 million cases of celiac disease in the U.S. by 2023. Topline results are anticipated in Q2 2022.

On October 6, 2021, Synthetic Biologics (NYSE American: SYN) reconvened its annual meeting of shareholders, but it was adjourned a second time due to insufficient quorum, with only 48.6% of shares present. The meeting will reconvene on October 14, 2021, at the company's headquarters to allow more time for shareholders to vote on proposals. The company is actively soliciting votes and has engaged a proxy solicitor to aid in achieving quorum. Shareholders are encouraged to vote by October 13, 2021.

On September 21, 2021, Synthetic Biologics (NYSE American: SYN) held its annual shareholder meeting, which was adjourned without conducting business due to a lack of quorum. Only 46.2% of shares were voted, below the required majority. The meeting will reconvene on October 6, 2021, at the company's headquarters to allow more time for shareholder voting. The firm has engaged D.F. King & Co. to help solicit votes and urges shareholders to cast their votes by October 5, 2021.

Synthetic Biologics (NYSE American: SYN), a clinical-stage company focusing on gastrointestinal diseases, announced a clinical update and financial results for Q2 2021. They reported a cash position of approximately $74.3 million, enabling the progress of clinical trials for SYN-004 and SYN-020 through 2023. The company completed patient dosing for the Phase 1 trial of SYN-020, achieving positive safety results. Future milestones include a Phase 1 multiple-ascending dose trial expected to start in Q3 2021 and topline data from SYN-004 anticipated in Q4 2021.